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Retention of activity by selected anthracyclines in a multidrug resistant
human large cell lung carcinoma line without P-glycoprotein
hyperexpression
H.M. Coley*, P. Workman & P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Hills Road, Cambridge CB2 2QH, UK.
Summary A subline (COR-L23/R) of the human large cell lung cancer line COR-L23, derived by in vivo
exposure to doxorubicin, exhibits an unusual multidrug resistant (MDR) phenotype. This subline shows
cross-resistance to daunorubicin, vincristine, colchicine and etoposide but does not express P-glycoprotein.
Interestingly, COR-L12/R shows little or no resistance to a range of structurally-modified analogues of
doxorubicin comprising 9-alkyl and/or sugar modified anthracyclines. We have previously identified these same
compounds as effective agents against P-glycoprotein-positive MDR cell lines. In contrast to typical MDR cell
lines, COR-L12/R shows only minimal chemosensitisation by verapamil and no collateral sensitivity to
verapamil. Compared to the parental cell line, COR-L12/R displays reduced accumulation of doxorubicin and
daunorubicin. Accumulation defects were apparent only after 0.5-1 h of incubation of cells with these agents.
The rate of daunorubicin efflux was shown to be enhanced by COR-L12/R and this efflux was demonstrated
to be energy-dependent. The use of anthracyclines which retain activity in MDR cells thus appears to be a
valid approach for the circumvention of MDR, not only in cells which express P-glycoprotein, but also where
defective drug accumulation is due to other mechanisms possibly involving an alternative multidrug trans-
porter.
The hyperexpression of membrane P-glycoprotein is now a
well established correlate of multidrug resistance (MDR) in
cultured cancer cell lines (Juliano & Ling, 1976; Kartner et
al., 1983; Endicott & Ling, 1989). There are, however, a
number of reports describing cell lines which exhibit cross-
resistance to the usual range of amphipathic high molecular
weight natural products normally associated with MDR, but
which do not show P-glycoprotein hyperexpression. For
example, the presence of P-glycoprotein could not be detect-
ed in an HL-60 human leukaemia cell line with in vitro
acquired resistance to doxorubicin (Marsh & Center, 1987).
However, a phosphorylated protein designated P-150 was
isolated from membrane preparations of the drug resistant
but not the drug sensitive variant (Marsh & Center, 1987).
Similarly an MDR variant of the human small cell lung
cancer line NCI-H69 was derived by in vitro by exposure to
doxorubicin and likewise did not express P-glycoprotein
(Mirski et al., 1987). This latter report contrasts strikingly
with the observation in our laboratory that in a different
MDR variant of the NCI-H69 cell line, also derived by in
vitro exposure to doxorubicin, there is clear membrane P-
glycoprotein hyperexpression as well as mdr gene ampli-
fication (Reeve et al., 1989a). Whereas it has become
accepted that P-glycoprotein acts as a drug efflux pump and
that defective drug accumulation is usually associated with its
hyperexpression (Endicott & Ling, 1989; Fojo et al., 1985;
Kessel & Corbett, 1985), the mechanistic basis for MDR in
the absence of P-glycoprotein remains to be elucidated.
Two therapeutic approaches have been taken to the prob-
lem of MDR in the hope of eventual application in a clinical
setting. One has been the use of 'resistance modifiers' such as
verapamil which at least partially restore sensitivity in MDR
cells to the agents to which they have become resistant
(Tsuruo et al., 1983, 1984; Ramu et al., 1984; Kessel &
Wilberding, 1985; Kessel, 1985). The other approach involves
the identification of analogues of MDR-associated drugs
which retain activity in resistant cells, most probably because
they are not effluxed as efficiently by P-glycoprotein (Twenty-
man et al., 1986a; Scott et al., 1986; Coley et al., 1989a). In
previous studies we have shown with our P-glycoprotein-
positive cell lines that these include anthracyclines having
either a 9-alkyl substitution in the A-ring or sugar modifi-
cations such as replacement of the amino group of the
daunosamine moiety with a morpholinyl ring (Scott et al.,
1986; Coley et al., 1989a). There may be a particular advan-
tage for combining both moieties within the same molecules,
as in the analogue MX2 (Coley et al., 1990). We were further
able to demonstrate a cellular pharmacokinetic basis for such
differential retention of activity and also for the action of
resistance modifiers verapamil and cyclosporin A (Coley et
al., 1989b).
Recent reports from this laboratory (Twentyman et al.,
1989b; Reeve et al., 1990) have described an MDR variant of
the human large cell lung cancer cell line COR-L23 (Baillie-
Johnson et al., 1985). This variant, COR-L23/R, was derived
by in vitro exposure to doxorubicin and shows cross-resis-
tance to vincristine and colchicine. However, it does not
hyperexpress the mdr I gene as determined by Northern blot-
ting or its product, P-glycoprotein, as determined by Western
blotting or immunocytochemistry with antibody C219 (Kart-
ner et al., 1985). It does, however, show reduced expression
of the EGF receptor (Reeve et al., 1990). We now report on
the sensitivity of COR-L23/R to 'low-resistance anthracy-
clines', the degree of resistance modification by verapamil,
and the differences in cellular pharmacokinetics between the
resistant and parent lines. A preliminary report of these
studies has appeared in abstract form (Coley et al., 1989c).
Materials and methods
Cell lines and culture conditions
The human large cell lung cancer parental cell line COR-L23/P
was derived in this laboratory (Baille-Johnson et al., 1985)
and doxorubicin-resistant variant COR-L23/R was developed
from it by continuous step-wise in vitro incubation with
increasing concentrations of doxorubicin (Twentyman et al.,
1986b). COR-L23/R was maintained in culture in the pre-
sence of 0.2 jig ml-' doxorubicin. Parental and drug resistant
cell lines were grown as monolayer cultures in RPMI
medium (Gibco, Paisley, UK) with 10% foetal calf serum
(Seralab, Crawley Down, UK), penicillin and streptomycin
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(at concentrations 100 units ml' and 100 g ml1', respec-
tively). Stock cultures were maintained in 15 ml ofmedium in
75cm' tissue culture flasks at 37C in an atmosphere of92%,
air 8% CO2.
Cell for use in experiments were harvested in the exponen-
tial phase of growth and the COR-L23/R line grown in
drug-free medium at least 2 days prior to experiments. Cell
lines were subjected to two rinses oftrypsin (2%) and versene
(0.02%) in PBS and incubated for 15min. Cells were resus-
pended in medium and reduced to a single cell suspension by
mechanical disaggregation.
Drugs and chemicals
We are grateful for the gifts of doxorubicin and 4'-deoxy-4'-
iodo-doxorubicin (iodo-doxorubicin) from Dr Fredrico Spre-
afico, Farmitalia Carlo Erba, Milan, Italy; aclarubicin from
Dr David Allen, Lundbeck Ltd, Luton, UK; Ro 31-1215
from Dr Joe Martin, Roche Products Ltd, Welwyn Garden
City, UK; morpholinyl doxorubicin from Dr Ed Acton, MD
Anderson Hospital and Tumour Institute, Houston, Texas,
and US National Cancer Institute, Bethesda, Maryland,
USA; and MX2 from Dr Takeshi Uchida, Kirin Brewery
Company, Tokyo, Japan.
Vincristine sulphate was obtained from David Bull Labor-
atories Ltd, Warwick, UK; colchinine and daunorubicin were
obtained from Sigma Laboratories, Poole, UK; etoposide
was obtained from Bristol-Meyers Pharmaceuticals, Slough,
UK; verapamil was supplied by Abbot Laboratories, Queen-
borough, UK.
3H-daunorubicin (specific activity 4.2 Ci mmol ') was
obtained from New England Nuclear Research Products,
Boston, USA.
Cytotoxic drugs were dissolved directly in sterile distilled
water at 500 Lg ml-l in the case of doxorubicin, dauno-
rubicin, Ro 31-1215, aclarubicin, iodo-doxorubicin, morpho-
linyl doxorubicin and MX2 and sterilised by membrane
filtration. Colchicine was similarly prepared by at 200ILg ml1'. Verapamil was obtained as a 2 mgml1' aqueous solu-
tion in sealed ampoules and diluted in PBS immediately prior
to use. Vincristine was obtained as a sterile lyophilised plug
and reconstituted with sterile distilled water to give a stock
solution of 500 tgml-'. Etoposide was obtained as a solu-
tion of concentration 20 mgml-' in an ethanol-based sol-
vent, in sealed ampoules. This was diluted in sterile distilled
water to give a final working solution of 500 gml-.
Chemosensitivity testing using the MTTassay
This was carried out as previously described (Coley et al.,
1989a; Twentyman & Luscombe, 1987). Briefly, cell suspen-
sions were dispensed in 200 ,l aliquots into 96 well tissue
culture plates (Falcon Plastics, Cowley, UK) to give 1 x 103
and 2 x I03cells/well for COR-L23/P and COR-L23/R
respectively. The plates were then incubated for 2-3 h at
37°C to allow medium equilibration and cell attachment.
Drugs were then added to the wells in a volume of 20 ll to
produce the final concentration required. The range selected
encompassed drug doses estimated to produce a decrease in
final optical density to less than 10% of that given by the
control, drug-free cells.
Cells were exposed continuously following a single drug
administration for a 6 day period at 37°C during which time
there was a 10-20-fold increase in cell number for untreated
control cells. MTT solution (5 mg ml-' in PBS, Sigma,
Poole, UK) was then added to each well in a volume of 20 ILI
and the plates incubated for 5 h at 37°C. The medium was
then aspirated from the wells and 200 LIl of DMSO (BDH,
Poole, UK) was added to dissolve the crystalline formazan
reaction product. The plates were agitated for 10 min and
absorbances were read on a Titertek Multiskan MCC ELISA
plate reader (Flow Laboratories, Rickmansworth, UK) at a
measuring wavelength of 540 nm and a reference wavelength
of 690 nm. Absorbance values obtained were expressed as a
fraction of those obtained for control wells. In all experi-
ments 3-6 replicate wells were used for each drug concentra-
tion.
Effects ofverapamil on chemosensitisation
Verapamil was added to wells in a volume of 10Il, 2-3 h
after cell inoculation to give a final concentration of 3.3 lAg
ml-' (6.6pLM). The plates were incubated at 37°C for a
further 2-3 h before the addition of the cytotoxic agents.
For determination of the sensitivity to verapamil alone, how-
ever, the drug was added in a total volume of 20 lI. The
MTT assay was then performed as above.
Cellularpharmacokinetics
Anthracycline accumulation The method used to determine
the anthracycline content per cell was essentially that of
Schwartz (1973). Doxorubicin and aclarubicin were used at
working concentrations of 10 1gml-' and iodo-doxorubicin
and Ro 31-1215 at 1 pgml-' (according to the intrinsic
fluorescence of the individual compounds). Cell suspensions
(106 cells in 5 ml) were brought to 37°C and drug solutions
were added in 100 tl volumes. During the incubation period,
the tubes were agitated at 10min intervals.
At the appropriate time points the tubes were centrifuged
rapidly at 4°C (300g for 2 min) and the cells washed twice in
ice-cold PBS. A volume of 0.2 ml of ice-cold silver nitrate
solution (33% w/v) was then added followed by a further
10min shaking period and centrifugation for 5 min at 200g.
At the end of this time period, 4 ml of iso-amyl alcohol was
added followed by a further 10 min shaking period and
centrifugation for 5 min at 200g. The alcohol layer was then
transferred to a 4 ml boro-silicate test tube and the
fluorescence proportional to drug content was measured
using a MPF4 fluorescence spectrophotometer (Perkin Elmer,
Connecticut, USA). Standards were prepared by adding
known amounts of anthracyclines to sodium lauryl sulphate
and silver nitrate. The excitation (Ex) and emmission (Em)
wavelengths for the spectrofluorimetric analysis of the
various anthracyclines were as follows: doxorubicin 490 Ex,
595 Em; iodo-doxorubicin 480 Ex, 590 Em; Ro 31-1215
485 Ex, 565 Em; aclarubicin 450 Ex, 570 Em.
3H-daunorubicin accumulation and efflux Cells were set up in
triplicate in 3 cm diameter wells on 6-well plastic tissue
culture plates (Sterilin Ltd, Feltham, UK) at a concentration
of 8 x 104 well for COR-L12/P and 9 x 104 well for COR-
L23/R. The resulting monolayer cultures were used after 4
days of incubation at 370C at which time they had reached
the exponential phase of growth. Experiments were carried
out using unlabelled daunorubicin at a concentration of
0.4 ig ml-' together with 0.1 sCi mj1 3H-daunorubicin in
complete RPMI. The appropriate mixture of labelled and
unlabelled compounds was added in a volume of 2ml of
fresh medium to the appropriate wells following removal of
the growth medium. The dishes containing drug and medium
were then incubated at 370C. In efflux experiments, a 60 min
loading period was used followed by removal of the medium,
rinsing and addition of fresh medium. After the appropriate
incubation period, the wells were aspirated dry and the
monolayer rinsed twice in 2 ml of ice-cold PBS. The treated
monolayers were then lysed with 0.01% sodium dodecyl
sulphate in aqueous solution for 20 min. The resulting lysate
was mixed by rapid pipetting and 500 l aliquots added to
scintillation vials containing 5 ml of Quickzint 401 (Zinsser
Analytic, Maidenhead, UK) scintillation fluid. The vials were
counted for tritium in a Beckman LS 5000CE liquid scintilla-
tion counter for 10min, and the results were expressed as
counts per minute (cpm) per I05 cells following background
subtraction. Cell counts were carried out on duplicate wells
using trypsin/versene to produce a single-cell suspension. For
this the cells were resuspended in 1 ml of medium and 500IsI
aliquots dispensed into 20 ml of Isoton II (Coulter Elect-
ronics, Luton, UK). Cell suspensions were then counted
using a Coulter ZBI particle counter (Coulter Electronics,
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Energy-dependent anthracycline efflux In these experiments,
doxorubicin and daunorubicin were each used at a concent-
ration of 3 sgml-1. Cells were suspended in glucose-free
Eagles' minimal essential medium with the addition of 10tLM
sodium azide. Cell suspensions were incubated for approx-
imately 10min to reach 37°C. At time zero the appropriate
compound was added and the initial influx measured at the
time points indicated by sampling of the cell suspension
followed by washing and processing as for drug accumula-
tion experiments. At 30 min either 20 mM glucose in PBS or
the same volume of PBS (100fil) as solvent control was
added and the cell suspensions sampled at various times
thereafter. The method is similar to that employed previously
by others (Dano, 1973; Inaba & Johnson, 1978).
Results
Chemosensitivity testing
Data in Table I illustrate the cross-resistance patterns for
COR-L23/R. These results are consistent with a typical
MDR phenotype. The resistance factor
(RF = ID50 COR-L23/R
ID50 COR-L23/P
was approximately 17 for the inducing agent, doxorubicin,
and rather higher values were obtained for vincristine (26)
and particularly for etoposide (50). Daunorubicin and col-
chicine gave slightly lower RFs than that for doxorubicin. It
is interesting to note that the anthracycline analogues Ro
31-1215, iodo-doxorubicin, aclarubicin, morpholinyl doxo-
rubicin and MX2 all gave very low RF values.
Collateral sensitivity to verapamil was not seen in COR-
L23/R. The ID50 values of verapamil were shown to be
60p1gml-' for COR-L23/P and 63 igml-' for COR-L23/R
(means from two separate experiments).
Table II shows the chemosensitisation by VRP at 3.3fg
ml-' (6.6 gM). The sensitisation ratio (SR) values obtained
overall were modest. The highest values were obtained with
vincristine at around 4-fold. Sensitisation of COR-L23/R to
etoposide and doxorubicin was similar (around 2.5-fold) des-
pite the very much higher level of resistance to the former
shown by this line. There was essentially no effect of vera-
pamil when combined with the anthracycline analogues
which gave low RFs
Cellularpharmacokinetics
Anthracycline accumulation Doxorubicin accumulation in
the COR-L23 cell lines as measured by fluorescence is shown
in Figure la. Reduced cellular accumulation was seen for
doxorubicin in COR-L23/R, but this was only evident for
Table II Verapamil sensitisation in the COR-L23 cell lines
Sensitisation ratio*
Compound COR-L23/P COR-L23/R
Doxorubicin 1.27 2.52
1.25 2.50
Daunorubicin 1.40 3.90
Vincristine 2.70 4.0
1.70 4.3
Colchicine 1.71 3.80
Etoposide 1.43 2.50
1.40 2.20
Ro 31-1215 1.00 1.00
0.93 1.46
lodo-doxorubicin 1.00 1.60
1.00 1.37
Aclarubicin 1.50 0.87
0.67 1.20
*Sensitisation ration (SR).
ID50 obtained in the absence ofverapamil
ID5o in the presence ofverapamil
Results are shown for independent experiments.
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Table I Cross-resistance profile for the COR-L23/R cell line
ID50 (igml-') ID50 (Lgml') Resistance
Compound COR-L23/P COR-L23/R factor*
Doxorubicin 0.057 1.2 16.9 (3.1)
Daunorubicin 0.018 0.50 9.9 (5.2)
Vincristine 0.0069 0.10 25.5 (6.9)
Colchicine 0.0022 0.026 12.1 (2.1)
Etoposide 0.42 15.0 49.9 (6.9)
Ro 31-1215 0.17 0.68 3.26 (1.6)
4'-deoxy-4'-iodo- 0.070 0.19 2.43 (1.2)
doxorubicin
Aclarubicin 0.053 0.046 1.44 (0.7)
Morpholinyl 0.010 0.013 1.25; 1.57**
doxorubicin
MX2 0.036 0.061 1.36; 2.17**
*Resistance Factor = ID50 for COR-L23/R
ID,, for COR-L23/P
Values are the means obtained from 3-4 experiments and numbers in
parentheses give the standard deviation. **Two experiments only -
individual values are given.
Figure 1 a, The accumulation ofdoxorubicin (10 lgml-') in the
COR-L23 cell lines. (@) COR-L23/P, parent drug-sensitive line;
(0) COR-L23/R, doxorubicin-resistant variant. Results are from
a single experiment with duplicate samples showing a variation
< 10%. Similar results were obtained in two independent experi-
ments. b, The accumulation of 3H-daunorubicin (0.4figml-1;
0.1 lCi ml-') in the COR-L23 cell lines. Symbols are as for
Figure la. Results are from a single experiment. Data points are
the mean oftriplicate analyses with a CV <21%). Similar results
were obtained in two further independent experiments.
60 min incubation with the drug. With 3H-daunorubicin a
similar accumulation defect was observed after 30 min
(Figure lb). Table III gives results for cellular accumulation
of various anthracyclines following I and 4 h incubation. The
data for doxorubicin indicate the steady state level to be
reached fairly rapidly in COR-L23/R, as the results for 1 and
4 h appear similar. No differential between parent and resis-
tant lines was seen for the cellular accumulation of acla-
rubicin or iodo-doxorubicin.
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Table III Drug accumulation in the COR-L23 cell lines
Drug content (1tg 10-6 cells)
Compound 1 h 4 h
COR-L23/P COR-L23/R COR-L23/P COR-L23/R
Doxorubicin 1.9, 1.3 1.8, 1.2 2.9, 2.7 1.4, 1.3
Iodo-doxorubicin 1.7, 1.7 1.7, 1.7 3.2, 4.0 3.4, 4.1
Aclarubicin 11.5, 12.0 12.0, 12.2 13.2, 17.2 13.3, 17.4
Results are from two independent experiments (each performed in duplicate).
Drug accumulation in the presence of verapamil 3H-dauno-
rubicin accumulation was unchanged in the COR-L23/P line
but was increased by around 60% in the COR-L23/R line
(Figure 2). However, the enhanced DNR accumulation
remained no more than 60% of the level seen for the paren-
tal COR-L23/P line. Thus, verapamil could only partially
correct the accumulation defect seen in COR-L23/R.
Efflux of 3H-daunorubicin Following a 60 min loading with
3H-daunorubicin and transfer to drug free medium, drug
efflux was significantly enhanced in COR-L23/R compared to
the parental line (Figure 3). At 60 min the cellular drug levels
were found to be approximately 55% and 20% of the load-
ing levels for COR-L23/P and COR-L23/R, respectively.
Energy-dependent drug efflux Upon the addition of glucose
to cells in drug-containing, glucose-free medium with azide,
there was very little effect on cellular doxorubicin content of
the COR-L23 parent and resistant lines (Figure 4). This
suggests no substantial energy-dependent doxorubicin efflux
for COR-L23/R. Results in Figure 5, however, do provide
evidence for an energy-dependent efflux of daunorubicin in
COR-L23/R.
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Figure 3 The efflux of 3H-daunorubicin in the COR-L23 cell
lines. Cells were preloaded with 3H-daunorubicin (0.4tg ml-';
0.1ItCi ml- ) for I h. (0) COR-L23/P parent, drug-sensitive line,
(0) COR-L23/R drug-resistant variant. Data are from a single
experiment with duplicate samples showing a variation of
<10%. Similar results were obtained in an independent repeat
experiment.
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Figure 2 Effect of verapamil (3.3 jigml-') on the accumulation
of 3H-daunorubicin (0.4 gml-'; 0.ICi ml-) in COR-L23 cell
lines. (-) COR-L23/P parent, drug-sensitive line control, (A) in
the presence of verapamil; (0) COR-L23/R drug-resistant
variant control, (A) in the presence of verapamil. Results are
from a single experiment. Data points are the mean of triplicate
analyses with a CV of <21%. Similar results were obtained in
two further independent experiments.
Discussion
The finding that cell line COR-L23/R, derived by in vitro
exposure to doxorubicin, fails to exhibit P-glycoprotein has
provided us with a model to examine in detail the relation-
ship between the expression of this putative multidrug trans-
porter and various other features of the MDR phenotype.
The line shows cross-resistance to vincristine, coichicine and
etoposide but essentially no cross-resistance to the anthracy-
clines Ro 31-1215, iodo-doxorubicin, aclarubicin, morpho-
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Figure 4 Determination of energy-dependent efflux of doxo-
rubicin present at 3lg ml in glucose-free, drug-containing
medium with 10mM azide. (0) COR-L23/P control, (0) with
addition of 20mM glucose; (A) COR-L23/R control, (A) with
addition of 20mM glucose. Arrow denotes time of addition of
20 mM glucose or solvent control. Data are from a single experi-
ment (with duplicate points showing a variation < 12%). Similar
results were obtained in a subsequent repeat experiment.
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Figure 5 Determination of energy-dependent efflux of dauno-
rubicin present at 3 1g ml-l in glucose-free, drug-containing
medium with 10mM sodium azide. (0) COR-L23/P control, (0)
with addition of 20mM glucose; (A) COR-L23/R control, (A)
with addition of 20 mM glucose. Arrow denotes addition of
glucose or solvent control. Data are from a single experiment
(with duplicate points showing a variation < 12%). Similar
results were obtained in a subsequent repeat experiment.
linyl doxorubicin and MX2. In this regard, therefore, the
resistance profile is closely similar to that seen in our human
small cell lung cancer MDR line NCI-H69/LX4 and mouse
mammary tumour MDR cell line EMT6/AR1.0, both of
which hyperexpress P-glycoprotein (Coley et al., 1989a, 1990
and submitted for publication).
In contrast to the results of the P-glycoprotein-positive
MDR lines, chemosensitisation by verapamil is, however,
very modest in COR-L23/R. The highest SRs are seen for
vincristine and colchicine. There is also some sensitisation of
COR-L23/P. These results are in agreement with previous
reports that describe the lack of verapamil-sensitisation seen
in non-P-glycoprotein expressing MDR cell lines (Cole et al.,
1989; Harker et al., 1989), and therefore with the concept
that P-glycoprotein hyperexpression is a necessary correlate
of differential verapamil sensitisation (Croop et al., 1987).
Hypersensitivity to verapamil alone has been found to be a
feature of some, but not all, P-glycoprotein
- hyperexpressing
MDR cell lines (Reeve et al., 1989b). Clearly no such hyper-
sensitivity is seen for COR-L23/R.
The anthracycline accumulation profiles in Figure 1 are
distinctly different from those obtained for typical MDR cell
lines with membrane P-glycoprotein hyperexpression (Fojo et
al., 1985; Kessel & Corbett, 1985; Coley et al., 1989b). Such a
pattern of accumulation was, however, previously reported
for an doxorubicin-resistant HL-60 cell line which did not
express P-glycoprotein (Marsh et al., 1986). As for the COR-
L23/R cell line, accumulation of doxorubicin or dauno-
rubicin was similar in parent and resistant lines over the first
half to 1 h, but at later times lower levels were seen in the
resistant line. Furthermore an increased ability to efflux
daunorubicin is seen in COR-L23/R (Figure 3) and this
ability is energy-dependent (Figure 5). The energy depen-
dence of doxorubicin efflux is more equivocal (Figure 4).
However, enhanced efflux is generally less for doxorubicin
than for daunorubicin, even in P-glycoprotein-positive MDR
cell lines (Inaba et al., 1979). The reason for this is unclear
but may possibly be due to different intracellular binding
characteristics of the two anthracyclines. The precise mechan-
ism for the delayed activation of this type of energy-depen-
dent efflux process also remains unclear. The data in Table
III demonstrate clearly that the absence of resistance to
iodo-doxorubicin and aclarubicin seen in COR-L23/R is
associated with improved accumulation over that seen for
doxorubicin.
From the results described herein, COR-L23/R is clearly
another example of atypical MDR. Following the description
of the HL-60 line (see above) (Marsh et al., 1986) the next
report of an MDR cell line without P-glycoprotein expression
described an MDR variant of the CEM human lymphoblas-
toid leukaemia cell line selected for resistance to teniposide
(Danks et al., 1987). The cell line showed cross-resistance to
many natural product cytotoxic agents including etoposide,
but retained sensitivity to vinca alkaloids. However, the
ability to accumulate etoposide was unaltered from that of
the parental line. The resistance seen in this cell line was
attributed to a decrease in the catalytic activity of, and DNA
cleavage by, the nuclear enzyme topoisomerase II (Danks et
al., 1987, 1988). Such a mechanism has also been invoked to
explain atypical MDR in a small cell lung cancer line GLC4/
ADR (Zijistra et al., 1987). This line, however, was not
resistant to colchicine or actinomycin D but did show defec-
tive doxorubicin accumulation. Atypical MDR in a resistant
leukaemia cell line derived from a patient with refractory
disease following chemotherapy has also been reported
(Haber et al., 1990). The line showed vincristine resistance
and no P-glycoprotein hyperexpression as determined using
the C-219 antibody. However, no pre- and post-treatment
comparisons were made and the authors used the leukaemic
CCRF-CEM cell line as the drug sensitive reference. Thus
the report, whilst interesting, should be regarded with some
caution. COR-L23/R also shares some properties with a
doxorubicin-resistant fibrosarcoma line HT 1080/DR4 (Slo-
vak et al., 1988) in that P-glycoprotein expression was absent
despite changes in drug accumulation and cross-resistance to
cytotoxics including vincristine. To date therefore, no con-
vincing explanation is available for the mechanistic basis of
cell lines such as COR-L23/R which show resistance to the
full spectrum of MDR drug, and also exhibit a drug accumu-
lation defect, yet do not hyperexpress P-glycoprotein.
A recent report (Marquardt et al., 1990) has described an
Mr 190,000 membrane-associated protein in an doxorubicin-
resistant variant of HL-60 cells with no P-glycoprotein. Close
structural homology to the ATP binding site on P-glyco-
protein has been demonstrated using a panel of antibodies
against specific sequences of P-glycoprotein and hence P-190
is proposed to be an alternative drug efflux protein. However,
no reactivity with the P-glycoprotein C-219 antibody (Kart-
ner et al., 1985) was seen, as was the case for COR-L23/R
(Reeve et al., 1990). In view of a demonstrable capacity to
efflux daunorubicin, COR-L23/R may too possess an alterna-
tive multidrug transporter.
The very high levels of drug resistance seen in many P-
glycoprotein expressing cell lines may not of course be
relevant to drug resistance as seen in the clinic. However, for
tumour types which have been shown in patients to express
P-glycoprotein, the mRNA levels can be higher than those
seen in a human cell line which is 4- and 6-fold more
resistant to doxorubicin and vinblastine respectively than the
parent line (Goldstein et al., 1989). A comprehensive study of
lung cancer cell lines derived from untreated or previously
treated small cell lung cancer patients (Carmichael et al.,
1985) showed mean relative resistance of the latter to doxo-
rubicin, vincristine and etoposide of 4.8, 2.6 and 9.4-fold
respectively. It was subsequently shown that the lines from
the previously treated patients do not show increased P-
glycoprotein expression as compared to the untreated lines
(Lai et al., 1989). In the case of lung cancer, therefore, the
very high levels of resistance with P-glycoprotein hyperex-
pression seen in MDR line NCI-H69/LX4 may not be a good356 H.M. COLEY et al.
model for clinical resistance. The lower levels of resistance
without P-glycoprotein hyperexpression seen in H69/AR
(Mirski et al., 1987) and now in COR-L23/R may be more
relevant.
With regard to therapeutic strategies, our results indicate
that the use of verapamil and possibly other resistance modi-
fiers may not be effective where resistance is not associated
with P-glycoprotein hyperexpression. On the other hand, the
strategy which we have described (Twentyman et al., 1986a;
Scott et al., 1986; Coley et al., 1989a, 1990) of using anthra-
cycline analogues which do not show reduced accumulation
in MDR cells is effective both in the presence and absence of
P-glycoprotein. It therefore may have more general applic-
ability. The mechanisms by which the analogues maintain
accumulation in COR-L23/R is unclear, but may involve
avoidance of an alternative energy-dependent multidrug
transporter.
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